You are here

Network Meta-Analysis Shows a Significant Advantage of Nilotinib Over Imatinib in Chronic Myeloid Leukemia

sandy craine's picture
Submitted by sandy craine on Mon, 29/06/2015 - 2:50pm
Published in Oncology News · June 12, 2015 June 11, 2015 – Vienna, Austria – A comparison of different first-line treatment strategies for chronic myeloid leukemia in a network meta-analysis has shown a significant and relevant nilotinib advantage over standard imatinib 400 mg. This result, covering a patient population of 6314 patients, was reported at the 20th Congress of the European Hematology Society, from June 11 – 14, 2015.

Published in Oncology
News · June 12, 2015

June 11, 2015 – Vienna, Austria – A comparison of different first-line treatment strategies for chronic myeloid leukemia in a network meta-analysis has shown a significant and relevant nilotinib advantage over standard imatinib 400 mg. This result, covering a patient population of 6314 patients, was reported at the 20th Congress of the European Hematology Society, from June 11 – 14, 2015.

ENESTPath

Randomized Phase III Study to Assess the Effect of Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML

Randomized Phase III Study to Assess the Effect of Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML

STIM 2

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib

Pages